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Abstract
Background: A canine-specific immunoturbidimetric CRP assay, Gentian Canine CRP Immunoassay) with species-
specific controls and calibrators was introduced and recently evaluated on the clinical chemistry analyzer Abbott
Architect c4000 as well as on the Olympus AU600.
Aims of our study were 1) to independently evaluate the canine-specific CRP assay on the ABX Pentra 400 clinical
chemistry analyzer in comparison to the previously validated human-based immunoturbidimetric assay (Randox Canine
CRP assay) and 2) to assess the impact of different sample types (serum versus heparinized plasma) on the results.
Imprecision, accuracy, interference and the prozone effect were determined using samples from healthy and diseased
dogs (n = 278). The Randox Canine CRP assay calibrated with canine specific control calibration material served as a
reference method. Additionally, the impact of the sample type (serum and lithium heparin) was evaluated based on
samples of healthy and diseased dogs (n = 49) in a second part of the study.
Results: Linearity was present for CRP concentrations ranging from 4 to 281 mg/l. For clinically relevant CRP
concentrations of 7–281 mg/l, recovery ranged between 90 and 105% and intra- and inter-assay CVs ranged between
0.68% - 12.12% and 0.88% - 7.84%, respectively. CV was thus lower than 12.16%, i.e. the desired CV% based on
biological variation. Interference was not present up to a concentration of 5 g/l hemoglobin, 800 mg/l bilirubin and
10 g/l triglycerides. No prozone effect occurred up to 676 mg/l CRP. Method comparison study revealed a Spearman’s
rank correlation coefficient of rs = 0.98 and a mean constant bias of 5.2%. The sample type had a significant (P = 0.008)
but clinically not relevant impact on the results (median CRP of 30.9 mg/l in lithium heparin plasma versus 31.4 mg/l in
serum).
Conclusions: The species-specific Gentian Canine CRP Immunoassay reliably detects canine CRP on the ABX Pentra
400 clinical chemistry analyzer whereby both serum and heparin plasma can be used. The quality criteria reached on
the Abbott Architect c4000 and Olympus AU600 could be met.
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Background
C-reactive protein (CRP) is a major acute phase protein
(APP) in the dog. As a part of innate immune response,
APPs change their serum concentration in response to a
systemic inflammation [1–4]. In contrast to classic in-
flammatory markers such as the white blood cell count,
APPs react more rapidly and with a shorter half-life
period [1, 5]. According to their kinetics in response to a
pathological stimulus, positive APPs are classified as
major, moderate and minor APPs. While major APPs
show a 100- to 1000-fold increase within 24–48 h and
decrease rapidly, moderate APPs react with a 5- to 10-
fold increase within a period of 2–3 days and a slow de-
crease. In contrast, minor APPs react with a mild 1.5- to
2-fold increase [3]. Due to their marked, rapid increase,
especially major APPs are sensitive diagnostic and prog-
nostic measurands [6, 7] to monitor systemic inflamma-
tion. In dogs, an increase of CRP was shown in several
conditions including infectious diseases [8–11], immune
mediated diseases [12–14], neoplasias [12, 15, 16], and
surgery [17].
A canine species-specific enzyme-linked immunosorb-
ent assay (ELISA) [18] proved to be sensitive but too
time-consuming to be used for routine measurements of
canine CRP. First evaluation of immunoturbidimetric as-
says designed for the detection of human CRP showed
unsatisfactory interspecies cross-reactivity between ca-
nine CRP and human CRP-antibodies [19], which was
mainly attributed to a species-specific pattern of glyco-
sylation of the CRP molecule [20, 21]. Later, an immu-
noturbidimetric assay with a reasonable cross-reactivity
was evaluated [22].
In 2010, our group investigated three human-based
immunoturbidimetric test systems in comparison to a
species-specific ELISA [23]. However, application of hu-
man CRP reagents and heterologous control and calibra-
tion material may lead to unpredictable results with false
low values in dog samples [22, 24]. The growing interest
in standardizing and communicating the range of methods
of APP measurement in veterinary species [2, 24, 25] led
to the development of canine-specific assays with specific
calibrators and controls. Meanwhile, purified canine CRP
became commercially available and was used as calibrator
in human CRP assays [24]. Canine specific controls as in-
ternal quality material still had to be prepared out of
serum pools of healthy and diseased patients.
Recently, a species-specific immunoturbidimetric assay
for canine CRP (Gentian Canine CRP Immunoassay,
Gentian AS, Moss, Norway) became available and had
been validated by Hillström et al. 2014 on the Abbott
Architect c4000 (Abbott Park, IL, USA) in comparison
to the Randox Canine CRP assay [26]. However, quality
performance differences between various clinical chem-
istry analyzers have been demonstrated previously [27]
making it difficult to both generalize results and com-
pare studies. Muñoz-Prieto et al. investigated the same
assay run on an Olympus AU600 analyzer but used the
heterologous Olympus CRP assay as a reference method
[28]. Apart from the analyzer, the sample material might
also have an impact on assay performance. Acute phase
proteins are commonly measured in serum, however,
sometimes only either serum or lithium heparin plasma
samples are submitted, when a clinical chemistry profile
including CRP is requested. Unfortunately it is not al-
ways possible to collect a further comparable sample. It
is therefore important to determine if both sample mate-
rials can be used interchangeably.
To the authors´ knowledge, the impact of the ABX
Pentra 400 as a different analyzer on the performance of
the Gentian CRP test as well as the effect of the sample
material (serum versus heparin plasma) has not been
evaluated so far. The aim of our study was thus to valid-
ate this assay with a different analyzer (i.e, Pentra 400
analyzer compared to the Abbott Architect c4000 and
Olympus AU600 analyzer, respectively) using a similar
methodology as the previous studies.
Our hypothesis was that the automated analyzer used
has only a minor impact on the test performance; how-
ever, the sample material (heparin plasma versus serum)
cannot be used interchangeably.
Methods
Study design
The present validation study was conducted between
April 2013 and March 2016.
The study was structured into two parts: First, method
validation was performed, including the evaluation of ac-
curacy, recovery, precision, interference, prozone effect,
and method comparison. The method comparison study
was conducted according to recent recommendations [29],
whereby the previously validated human-based immunotur-
bidimetric Randox Canine CRP assay (Randox Laboratories
Ltd., Crumlin, UK) [23] served as the reference method. In
the second part comparative measurements between lith-
ium heparin plasma and serum samples were conducted to
assess potential influence of an anticoagulant in order to
simplify future routine diagnostics by allowing the applica-
tion of both serum and heparin plasma samples.
Measurement of C-reactive protein
Both the Gentian Canine CRP Immunoassay and the Ran-
dox Canine CRP assay were run on the ABX Pentra 400
clinical chemistry analyzer (Horiba ABX SAS, Montpellier,
France).
Gentian canine CRP immunoassay
The canine-specific CRP assay (Gentian Canine CRP Im-
munoassay, Gentian AS, Moss, Norway) designed to be
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run on an automated analyzer is a quantitative immuno-
turbidimetric in-vitro diagnostic test using polyclonal
chicken-derived canine-specific anti-CRP antibodies.
The anti-CRP-immunoparticles aggregate with canine
CRP and form complexes that can be measured with
turbidimetric methods and are correlated with canine
CRP concentrations by interpolation on a calibration
curve. Calibration (Gentian Canine CRP Calibrator Kit,
Gentian AS, Moss, Norway) and the measurement of
canine-specific control material serving as internal qual-
ity control (Gentian Canine CRP Control Kit, Gentian
AS, Moss, Norway) were performed daily.
Randox canine CRP assay
In our study, LOT 1303404 of Randox Canine CRP assay
and - in contrast to the previous validation study [23]
but in accordance with the previous validation study for
the Gentian Canine CRP assay using the Randox Canine
CRP assay as the reference method - a canine calibrator
(Canine CRP Life Diagnostics, Inc., West Chester, USA)
was used. Using canine calibration material for the
human-based Randox Canine CRP assay, intra-assay CV
ranged between 0.7% - 2.1% (unpublished data).
Measurements were performed as batch analysis at
one day. Canine-specific calibration (Canine CRP Life
Diagnostics, Inc., West Chester, USA) was done before
the analyses were started while canine-specific control
measurements (Canine CRP Reference Standard Biozol
Diagnostica Vertrieb GmbH, Eching, Germany) were
performed prior to the analyses and after each measure-
ment of 60 samples.
Method validation
To avoid preanalytical error due to numerous dilution
steps, as it may occur by serially diluting a sample with
very high CRP concentration to achieve a very low CRP
concentration, linearity was evaluated in two dilution ex-
periments with a partially overlapping CRP range: Lin-
earity was first assessed by manual dilution of a canine
serum specimen with markedly increased CRP concen-
tration of 281.3 mg/l, achieving samples with 1.0, 0.8,
0.6, 0.4, 0.2, 0.1, 0.05, and 0.025 of the original CRP con-
centration. In addition, the diluted samples were used to
calculate the recovery rate at eight different CRP levels.
To gain more information about the test performance at
low CRP concentrations, linearity was also assessed by
manual, stepwise dilution of pooled canine quality control
material, whereby a normal and an abnormal control were
mixed in equal parts (Gentian Canine CRP Control Kit,
Gentian AS, Moss, Norway) so that a pooled sample with
a mean CRP concentration of 66.5 mg/l was obtained that
was then serially diluted to assess linearity at low CRP
concentrations. For all dilution steps, double-distilled
water was used as diluent to achieve samples with 1.0, 0.8,
0.6, 0.4, 0.2, 0.1, 0.05, 0.025 and 0.0125 of the original CRP
concentration of the pooled samples. All samples were an-
alyzed in triplicates in a single run. Intra-assay and inter-
assay repeatability including between-run and between-
day CV were determined by measurement of four canine
serum samples with different CRP concentrations (A:
7.2 mg/l, B: 58.4 mg/l, C: 103.9 mg/l, D: 272.1 mg/l). Sam-
ple analysis was carried out in duplicates twice daily
(morning and evening to assess between-run CV) over
5 days without recalibration. Sample order was changed
randomly every run.As recommended for a verification of
the limit of quantification [30], additional measurements
were performed to evaluate intra-assay precision specific-
ally for CRP values close to zero (A1: 2.3 mg/l, A2:
3.8 mg/l). Here, samples were analyzed 20 times in a sin-
gle run without recalibration.
Interference was investigated by spiking aliquots of a
canine serum sample of 35.5 mg/l CRP with 800 mg/l
bilirubin (Bilirubin, Sigma-Aldrich Co. LLC., St. Louis,
Missouri, USA), 5 g/l hemoglobin (Hemoglobin human,
Sigma-Aldrich Co. LLC., St. Louis, Missouri, USA) or
10 g/l 20% soy bean emulsion (Intralipid 20%, Fresenius
Kabi Canada, Ontario, Canada) before analyzing them in
triplicates in random order.
A stock solution containing bilirubin in a concentration
of 20 g/l was prepared by diluting 20 mg bilirubin in 1 ml
of 0.1 M NaOH. Then, 0.1 ml of the product was added to
2.4 ml non-spiked serum sample to achieve a bilirubin
level of 800 mg/l.Lyophilized human hemoglobin was dis-
solved in 0.09% NaCl (1 part in 10 parts of NaCl) so that a
stock solution containing 100 g/l hemoglobin was ob-
tained and 0.125 ml of the solution were added to
2.375 ml non-spiked serum sample to receive a
hemoglobin concentration of 5 g/l.To assess the impact of
lipemia on results, 0.125 ml of Intralipid were added to
2.375 ml of non-spiked serum sample resulting in concen-
tration of soya bean oil of 10 g/l.
The samples were compared to serum aliquots spiked
with an equal volume of either 100 mM NaOH (in case
of bilirubin), 0.09% NaCl (hemoglobin) or pure water (in
case of Intralipid). Antigen overload may provoke falsely
low CRP measurements. This so called prozone effect
was evaluated by spiking a serum sample containing a
very low CRP concentration with purified canine CRP
(Dog C-Reactive Protein, Life Diagnostics, Inc., West-
Chester, USA) until a CRP concentration of 1069.5 mg/l
was obtained. The spiked sample was subsequently di-
luted with 0.9% NaCl so that final concentrations of
455 mg/l, 676 mg/l, and 890 mg/l were achieved. Sam-
ples were measured in duplicates in a single run.
Method comparison study
In the method comparison study, the Gentian Canine
CRP Immunoassay was compared to the previously
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validated human-based immunoturbidimetric Randox
Canine CRP assay.
Overall, 278 serum samples of healthy and diseased
dogs presented at the Department of Clinical Sciences,
School of Veterinary Medicine, University of Liège,
Liège, Belgium, were analyzed with both immunoturbidi-
metric assays. The samples have already been used for a
previous study in which inflammatory cytokines and
CRP were investigated in canine systemic inflammatory
response syndrome patients [31]. In our study, residual
sample material was used.
Samples were collected between January and August
2010, stored at −80 °C and shipped frozen to the Depart-
ment of Veterinary Clinical Sciences, Clinical Pathology
and Clinical Pathophysiology, Justus-Liebig-University
Giessen, Germany, and stored again at −80 °C for
4 weeks until batch-analysis was performed.
Effect of sample material
To assess the impact of an anticoagulant (lithium hep-
arin plasma versus serum sample) on the CRP measure-
ments, blood samples of 49 healthy and diseased dogs
presented at the Clinic for Small Animals, Faculty of
Veterinary Medicine, Justus-Liebig University, Giessen,
Germany, were obtained simultaneously by venipuncture
with a sterile disposable cannula into tubes (1.3 ml) con-
taining lithium heparin as anticoagulant and tubes with-
out additives.
Inclusion criterion was that both a heparinized blood
sample and a serum sample were taken for diagnostic pur-
poses. Between March and April 2014, samples were ana-
lyzed in matched pairs within the first hour after blood
collection. Lithium heparin anticoagulated samples were
centrifuged for 1 min with 8944 g without delay, while
samples without additives were allowed to clot for at least
10 min after receipt in the laboratory. Intra-assay
repeatability for measurement of CRP in heparinized
plasma was first assessed for ten consecutive measure-
ments with samples from three dogs with low, moderate
and high CRP values (10, 53, 77 mg/l respectively). Add-
itionally, the LoQ of the CRP assay determined for serum
(A1, A2, Table 1) was verified for heparinized plasma as
well, whereby both the heparinized and the serum samples
were taken from the same dogs with CRP values close to
zero and analyzed 20 times.
Statistical analysis
Statistical analyses were carried out using statistical soft-
ware packages (MedCalc, software version 16.2.1; Ost-
end, Belgium and GraphPad Prism 6 Software,
GraphPad Software, Inc., La Jolla, USA).
Method validation study
Limits of acceptance were set according to Total allow-
able error (TE) guidelines of the American college of
Veterinary Clinical Pathology (ASVCP) [32]. Although
no definite TE for CRP was recommended by the work-
group, an optimal and desired coefficient of variation
(CV), bias, and TE based on biologic variation was given
in the addendum of the ASVCP guidelines: The optimal
/ desired allowable imprecision (CVopt/CVdes) were re-
ported to be 6.08% and 12.16% respectively, the optimal
and desired allowable bias (biasopt/biasdes) were 4.76% /
9.52% and the optimal / desired total allowable error
(TEopt/TEdes) were 14.79% / 29.58%, respectively [32].
Here, numbers rounded to one decimal place are used.
Descriptive statistics were performed to calculate
arithmetic means, standard deviations (SD), and CV. All
data were evaluated for normal distribution using the
Shapiro-Wilk Test.
To evaluate the linearity under dilution of the assay,
mean results of measured values were plotted against
Table 1 Precision of CRP determination in pooled serum samples with CRP concentrations below a clinical decision limit (A1 - A2)
as well as pooled serum samples with clinically relevant CRP concentrations
Intra-assay CV Inter-assay CV
Between run CV Between day CV
Level Mean
CRP concentration
(mg/l)
SD (mg/l) CV% SD (mg/l) CV% SD (mg/l) CV%
A1 2.3 0.72 31.1 n.d. n.d. n.d. n.d.
A2 3.8 0.35 9.3 n.d. n.d. n.d. n.d.
A 7.2 0.87 12.1 0.56 7.8 0.44 6.1
B 58.4 1.08 1.9 1.25 2.1 2.7 4.6
C 103.9 0.88 0.9 0.91 0.9 1.9 1.8
D 272.1 1.85 0.7 4.98 1.8 2.8 1.1
A1, A2: CVs for intra-assay imprecision of two canine serum pools analyzed 20 times in a single run without recalibration.
A – D: Inter- and intra-assay CVs of 6 canine serum pools analyzed in duplicates twice daily over 5 days.
CVs not fulfilling the quality specifications i.e., are higher than 12.2% [32] are marked in bold letters.Abbreviations: n.d. = not done, SD = standard deviation;
CV = coefficient of variation.
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theoretical CRP concentration. The ‘best fit’ line was
visually inspected for linearity. In addition, recovery after
dilution was calculated by subtracting the measured
CRP result from the calculated (expected) CRP concen-
tration according to the following formula:
Recovery % = measuredconcentration−expectedconcentrationexpectedconcentration x100:
Acceptance criteria for recovery rates were set at 80–
120% for samples as recommended previously for valid-
ation of immunoassays [33, 34]. The intra-assay CVs
were calculated as follows based on mean and standard
deviation (SD):
CV % = SDMean x100
For the interference study, non-spiked samples (con-
trol) and samples spiked with the interfering substances
(test) were measured in triplicates. Observed interfer-
ence effect (dobs) was computed as the % bias between
the means of the test and control specimens:
dobs %¼ meantest−meancontrolmeancontrol x100
In accordance with the literature, bias between control
and test sample was considered acceptable if the bias for
the interfering substance (i.e., dobs %) was smaller than
the allowable TE [35], i.e. 29.6% (TEdes), and 14.8%
(TEopt) for canine CRP [32].
Method comparison study
Data of the method comparison experiment were ana-
lyzed with Spearman’s rank correlation and Passing &
Bablok regression analysis. Bland-Altman difference plot
was performed to investigate % bias. In addition, the
total observed error TEobs was calculated to judge ac-
ceptability according to the quality specifications recom-
mended by the American Society for Veterinary Clinical
Pathology (ASVCP) [32]. TEobs was calculated using fol-
lowing formula:
TEobs = bias % + 2CV%.
Effect of sample material
Comparative measurements of plasma samples: Normal-
ity was assessed with a Shapiro Wilk test. Since data
were not normally distributed, Wilcoxon signed-rank
test was performed to assess potential differences be-
tween the methods. For method validation, Spearman’s
rank correlation as well as Passing-Bablok regression
and Bland-Altman analysis were performed.
Results
Method validation study
Results of the precision study are shown in Table 1. For
clinically relevant CRP concentrations ranging between
7.2 and 272.1 mg/l (concentrations A-D), both intra-
and inter-assay CVs fulfilled the quality specifications,
i.e., the CVs did not exceed 12.2% [32]. Intra-assay im-
precision <2% was present for clinically relevant CRP-
ranges >40 mg/l. Only for CRP concentrations of
2.5 mg/l, a CV markedly exceeding the desired CV was
noted, so that the LoQ was set above the lowest concen-
trations still fulfilling the quality specifications i.e.,
3.8 mg/l (≈ 4 mg/l). Evaluation of inter-assay precision
showed slightly higher inter-assay CVs of 0.88–7.84%
than intra-assay CVs.
The results of the linearity study for higher and lower
concentration ranges are demonstrated in Fig. 1, Table 2,
and Table 3. As shown in Fig. 1, there was an excellent
correlation between expected and measured values for
both concentrations ranges. Considering the LoQ, lin-
earity under dilution of the Gentian Canine CRP Im-
munoassay was present in a range of 4–281 mg/l for
serially diluted canine specimens (Figure 1). Recovery
rate ranged between 88.9–105.4% at expected CRP
values of 7.0–281.3 mg/l (Table 2) and thus fulfilling the
quality requirements. For CRP concentrations ranging
between 0.8 mg/l and 66.5 mg/l (Table 3), however, qual-
ity requirements were not fulfilled for the lowest CRP
concentrations of 0.8 mg/l and 1.7 mg/l, respectively.
Overall, no interference was detectable up to a concen-
tration of 5 g/l hemoglobin, 800 mg/l bilirubin and 10 g/l
soy bean oil (Table 4). Mean absolute bias between control
and spiked test samples was 0.1 mg/l, 0.6 mg/l and
1.6 mg/l respectively. At a clinically relevant CRP concen-
tration of about 30 mg/l, the systematic errors are lower
than TEopt for all interfering substances. No prozone ef-
fect was present up to a concentration of 676 mg/l CRP as
CRP values were measured correctly: The recovery rates
for high CRP concentrations were 130% for 455 mg/l,
121% for 676 mg/l and 28% for 890 mg/l, respectively.
Method comparison study
As demonstrated in Fig. 2, there was an excellent correl-
ation (rs = 0.98) between the results obtained with the
species specific canine CRP test and the reference
method. Passing-Bablok regression equation revealed
small constant and proportional errors reflected by an
intercept of −1.18 (with 95% confidence intervals (CI) of
−2.07 to −0.43 mg/l) and a slope of 0.99 (95% CI 0.97 to
1.08) (Figure 2). Bland-Altman analysis revealed a mean
constant bias of 5.2% (Figure 3). Taking the bias and the
inter-assay CV at the 4 different CRP concentrations (A-
D, Table 1) under consideration, TEobs was calculated
and results are shown in Table 5. TEobs ranged from
20.9% at low levels to 7.0–9.5% at higher levels B-D
(table 5). Overall, TEobs was < TEdes of 29.6% for all CRP
concentration levels and even < TEopt of 14.8% for the
clinically relevant concentration levels B-D [32].
Effect of sample material
Spearman’s rank correlation coefficient revealed an ex-
cellent correlation between CRP measurements obtained
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in serum and heparin plasma samples (rs = 0.995). There
was a significant (P = 0.008), but clinically not relevant
difference between the median CRP results obtained for
both sample types (30.9 mg/l for lithium heparin plasma
versus 31.4 mg/l for serum samples).Passing-Bablok re-
gression equation showed a small constant error with an
intercept of 0.29 and a small proportional error with a
slope of 0.97 (Figure 4). Bland-Altman difference plot
(Figure 5) revealed a mean bias of 4.3% between results
obtained with both sample types.
Discussion
Overall, the Gentian Canine CRP Immunoassay accur-
ately and precisely detects canine CRP similar to the
previously used human-based immunoturbidimetric
method on the ABX Pentra 400 clinical chemistry
analyzer.
Comparisons of results of the current and previous
studies evaluating the Gentian CRP test for different an-
alyzers are shown in Table 6. As seen in the table, com-
parable results have been obtained for the majority of
quality parameters demonstrated on the Abbott Archi-
tect c4000 [26] so that performance quality could be also
confirmed for the ABX Pentra 400. There are some
small differences that have the potential to be clinically
relevant including a different CRP concentration at
which a prozone effect occurs, a slightly different LoQ
and a different linearity range (table 6). The evaluation
on the Olympus AU600 revealed a LoQ lying between
the values of the other two studies (table 6). Linearity
and prozone effect were not investigated in comparably
high ranges as performed in the other studies. It remains
unclear if the differences between the studies are due to
pre-analytic or analytic factors. As such, evaluation of
these discrepant quality parameters for different types of
analyzer across laboratories is recommended. The main
discrepancy between the current and the study by Hill-
ström et al. is the CRP concentration at which a prozone
effect is seen which is markedly higher (1200 mg/l) in
the previous than in the current study (676 mg/l).
Muñoz-Prieto et al. mentioned the prozone effect to
occur above a CRP level of 400 mg/l but did not
Fig. 1 Linearity of CRP determination at a high (a) and low concentration range (b). (a) Linearity under dilution for measurement of a canine
serum sample originally containing 281.3 mg/l CRP. A serial dilution was performed to achieve 8 different CRP concentrations, i.e., 1.0, 0.8, 0.6, 0.4,
0.2, 0.1, 0.05, 0.025 parts of the original concentration (b) Linearity range of CRP determination for a canine serum sample containing 66.5 mg/l
CRP. A serial dilution was performed to achieve 9 different CRP concentrations i.e., 1.0, 0.8, 0.6, 0.4, 0.2, 0.1, 0.05, 0.025, 0.0125 parts of the
original concentration
Table 2 Linearity and recovery rates of CRP measurements in a clinically relevant range of 7.0–281.3 mg/l after serial dilution of a
canine serum sample containing 281.3 mg/l CRP
Dilution
Factor
Expected concentration
[mg/l]
Mean measured
concentration[mg/l]
Recovery
[%]
Bias[%] % bias < TEdes
(29.6%)
% bias < TEopt
(14.8%)
0.025 7.0 6.9 97.6 −2.4 Yes Yes
0.05 14.1 12.5 88.9 −11.1 Yes Yes
0.1 28.1 26.1 92.9 −7.1 Yes Yes
0.2 56.3 54.1 96.1 −3.9 Yes Yes
0.4 112.5 112.3 99.8 −0.2 Yes Yes
0.6 168.8 172.3 102.1 2.2 Yes Yes
0.8 225.0 237.3 105.4 5.4 Yes Yes
1 281.3 286.2 101.7 1.7 Yes Yes
Recovery rates not fulfilling the quality specifications of 80–120% are marked in bold letters as well as % bias between expected and measured mean CRP
concentration exceeding the desired (TEdes) and optimal total allowable error (TEopt) reported previously [32].
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evaluate higher levels [28]. The term prozone effect de-
scribes the event of false low values of the analyte in im-
munoassays due to an excess of the analyte and is based
on the saturation curve of the antibody binding capacity
for antigen. The high number of analyte particles in-
hibits the formation of antigen-antibody complexes as
all binding sites of the antibody are already occupied by
antigen. This mechanism can lead to a false low signal
detected by turbidimetry [36]. Regarding the origin of
the markedly different prozone effect observed here and
in the previous study, pre-analytic factors such as pipet-
ting errors are considered an unlikely cause. However,
analytical factors including analyzer performance, varia-
tions in test application or differences between variable
batches of the test are a likely explanation for the dis-
crepant prozone effect between the studies. Marked
batch-specific differences in test performance due to
manufacturing tolerances have been previously observed
for the human Randox CRP assay when applied for ca-
nine specimens [23, 24]. However, the marked variation
between different batches of the CRP assay was mainly
caused by the highly variable cross-reactivity between
anti-human-CRP antibodies applied in the test and ca-
nine CRP. In a canine species-specific CRP test, such
high variation is unlikely, however, differences between
various batches have to be evaluated in future studies.
Another possible explanation would be a variation be-
tween different batches of calibrators which could
influence the calibration curve in detail and therefore
cause small differences in CRP values reported. It is a
limitation of this study that it was not possible to dir-
ectly compare the performance of both analyzers using
the same batch of test reagents, calibrators and samples
to exclude batch related variances. The instrument set-
tings of the different analyzers used may contribute to a
variation of the CRP-concentration causing a prozone
effect. If the recommended standard instrument settings
[37] are used, however, no major differences between the
settings can be found. There is no pre-dilution of the
sample by both analyzers which could potentially influ-
ence a prozone effect. Moreover, minor differences be-
tween the analyzers such as a minimally different
measuring wave length (600 nm for the ABX Pentra 400,
604 nm for Abbott Architect c4000) are unlikely to have
a major impact on the occurrence of a prozone effect.
The use of latex particles reduces prozone effects [36]
as well as an endpoint measurement instead of a kinetic
analysis, but both factors were constant here as the same
assay was used on both analyzers.
In contrast, a different reagent volume and ratio of re-
agent to sample volume (270 μl of reagent 1, 75 μl of re-
agent 2, 3 μl sample volume for the ABX Pentra 400;
270 μl of reagent 1, 70 μl of reagent 2, 2 μl sample vol-
ume for Abbott Architect c4000) may be a possible ex-
planation for different CRP concentrations at which a
prozone effect occurs but it remains questionable if it is
Table 3 Linearity and recovery rates of CRP measurements at a lower concentration range of 0.8–66.5 mg/l obtained after serial
dilution of a canine serum sample containing 66.5 mg/l CRP
Dilution
Factor
Expected concentration
[mg/l]
Mean measured
concentration[mg/l]
Recovery
[%]
Bias[%] % bias < TEdes
(29.6%)
% bias < TEopt
(14.8%)
0.0125 0.8 0.3 36.1 −63.9 No No
0.025 1.7 2.0 122.5 22.5 Yes No
0.05 3.3 3.3 98.4 −1.6 Yes Yes
0.1 6.7 6.4 95.7 −4.3 Yes Yes
0.2 13.3 11.2 84.3 −15.7 Yes Yes
0.4 26.6 26.2 98.6 −1.4 Yes Yes
0.6 39.9 38.1 95.6 −4.4 Yes Yes
0.8 53.2 55.3 103.9 3.9 Yes Yes
1 66.5 65.9 99.2 −0.8 Yes Yes
For quality specifications regarding recovery rate and % bias, see Table 2.
Table 4 Interference effects of hemoglobin, bilirubin and lipid (soya bean oil) on CRP measurement performed with the new
automated species-specific immunoturbidimetric assay
Interferent CRPcontrol [mg/l] ± SD CRPtest [mg/l] ± SD Mean bias [mg/l] % bias % bias < TEdes (29.6%) % bias < TEopt (14.8%)
Hemoglobin 5 g/l 33.7 ± 0.7 34.3 ± 1 0.57 1.7 Yes Yes
Bilirubin 800 mg/l 34.8 ± 0.6 34.9 ± 1 0.13 0.37 Yes Yes
Soy bean emulsion 10 g/l 32.7 ± 0.2 34.4 ± 1 1.63 5.0 Yes Yes
Test samples (CRPtest) with a mean CRP value of 35.5 mg/l spiked with the interfering substances were measured in triplicates and compared to control samples
(CRPcontrol) spiked with equal amounts of the diluent used in the test sample. %Bias for the interfering substance was considered acceptable when it was <
desired total allowable error (TEdes) and excellent when it was < optimal total allowable error (TEopt) reported previously [32].
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the only explanation for the major differences between
prozone effects observed in the different studies. Al-
though CRP concentrations >680 mg/l are extremely
rare, septic dogs have been occasionally shown to have
high CRP ranges of up to 632 mg/l [6] and in dogs with
snake envenomation even CRP concentrations above
900 mg/l were detected [38].As the prozone effect was
shown to occur above a CRP concentration of 680 mg/l,
the issue of false low results in patients with these rarely
occurring extremely high CRP values is a consideration.
A correlation with other clinical and laboratory parame-
ters is therefore mandatory to detect samples needing a
pre-dilution before measurement.
The LoQ determined in the current study was slightly
lower than the LoQ determined in previous validation
studies [26, 28] (Table 6). In the current study, the LoQ
was derived solely from the replication experiment, i.e.
the quality goal was based on the CVdes published in the
addendum of the allowable total error guidelines of the
ASVCP [32] that had to be <12.16%. Muñoz-Prieto et al.
used a higher CV of <20% as decision criterion [28]. The
LoQ in the previous study by Hillström et al. was ob-
tained from the linearity experiment taking both the CV
and the bias between expected and measured values into
consideration, i.e. the quality goal was based on the
Fig. 2 Passing-Bablok regression analysis for canine C-reactive protein
determined in canine serum samples by use of a species-specific
immunoturbidimetric assay (Gentian Canine CRP Immunoassay) in
comparison to a previously validated human based immunoturbidimetric
test system (Randox Canine CRP assay) run with a dog calibrator. The
solid blue line illustrates the regression equation with its 95%-confidence
intervals (brown dotted line). The thin solid grey line represents the
identity line consistent with a perfect correlation of the two methods
Fig. 3 Bland-Altman difference plot for canine C-reactive protein
measured in canine serum samples with a new species-specific
immunoturbidimetric assay (Gentian Canine CRP Immunoassay) in
comparison to a validated human based test system (Randox Canine
CRP assay). The solid blue line demonstrates the mean % bias, the
thin solid grey line is consistent with the identity line. The dashed
brown lines show the limits of agreement, which are defined as the
mean difference plus and minus 1.96 times the standard deviation
(SD). The solid red line indicates the desired total allowable error
(TEdes) of 29.6% [32]. A small bias of 5.2% with a confidence interval
of 95% (green dotted lines) is present
Table 5 Observed total allowable error (TEobs %) calculated at
four different CRP levels taking the coefficient of variation (CV)
and the bias of 5.2% derived from the method validation study
under consideration
Level A B C D
CRP concentration mg/l 7.2 58.8 103.9 272.1
CV Between-run % 7.84 2.14 0.88 1.83
TEobs % 20.9 9.5 7.0 8.9
TEobs < TEdes Yes Yes Yes Yes
TEobs < TEopt No Yes Yes Yes
TEobs was < desired total error (TEdes) of 29.6% [32] for all CRP concentration
levels. TEobs % results exceeding the optimal TE (TEopt) of 14.8% [32] are
marked in bold letters.
Fig. 4 Passing-Bablok regression analysis detailing the comparison
between results of canine C-reactive protein (CRP) determined in
either serum samples or lithium heparin samples (Li-Hep) with the
Gentian Canine CRP Immunoassay. The solid blue line illustrates the
regression with its 95%-confidence intervals (brown dotted line). The
diagonal grey line is consistent with the identity line
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TEdes also published in the ACVCP guidelines. While both
approaches are justified, it has to be considered that using
the TEdes - and thus both bias and CV - is a more strin-
gent approach than just applying CVdes and is therefore
the most likely explanation for the LoQ set at a higher
CRP concentration than in the current study (6.8 mg/l
and 4.0 mg/l, Table 6). When regarding the results pub-
lished previously, a SD of 0.39 mg/l was observed at a
CRP concentration of 6.8 mg/l, consistent with a CV of
5.5% which would have fulfilled the quality goal of the
current study. While a similar study design would have
been preferable to allow an exact comparison between
both analyzers and thus the true analyzer-dependent ef-
fect, both studies have been planned independently from
each other in overlapping periods of time.
Possible contributing factors to differences between
the studies might be also pre-analytical errors, especially
due to pipetting as well as the impact of the analyzer.
Also the LoQ determined by Muñoz-Prieto et al. is
slightly higher (Table 6) which may be due to preanalyti-
cal or analyzer dependent conditions or influenced by
the exact CRP levels used to evaluate the limit. However,
the differences in LoQs observed in all three studies are
rather academic in nature than of true clinical relevance
as the clinical decision limit to differentiate between
healthy dogs or dogs with and without systemic inflam-
mation was 16.8 mg/l [38] and thus well above the LoQs
found here and in the previous investigation.
For CRP concentrations above the LoQ of 4 mg/l,
intra-assay and inter-assay CVs ranging between 0.68–
12.2% and 0.88–7.84% respectively were comparable to
or lower than CVs reported in previous studies evaluat-
ing human assays for canine specimens. Evaluated hu-
man assays included the Bayer CRP assay (Bayer CRP
TIA, Bayer plc, Newbury, Berkshire, United Kingdom:
inter- and intra-assay CVs 5.2% - 10.8% and 3% - 10.2%
[22]; the Randox CRP assay with human calibrator, Ran-
dox Laboratories Ltd., Crumlin, United Kingdom: inter-
and intra-assay CVs with human calibrator: 1% - 10%
and 18% [23]; the Randox CRP assay with canine cali-
brator, Randox Laboratories Ltd., Crumlin, United King-
dom: intra-assay CV: 0.7% - 2.1% (own unpublished
data); and the Olympus CRP assay, CRP OSR 6147,
Olympus Life and Material Science Europe GmbH, Lis-
meehan, O′Callaghan’s Mills, Ireland 6147: inter- and
intra-assay CVs: both <10% [39]). When regarding solely
canine species specific CRP assays, inter- and intra-assay
CVs obtained for the Gentian CRP test here and in the
previous investigation by Hillström et al. (Table 6) were
markedly lower than for a commercially available canine
CRP ELISA test kit and this can be attributed to the
higher variation observed in manual methods (Phase
Range canine CRP, Tridelta Development Ltd., Kildare,
Republic of Ireland: inter- and intra-assay CVs: 6.9% -
10.1% and 7.5% - 29%) [18]. Muñoz-Prieto et al. showed
a similarly low intra-assay CV of 1.0–1.3% for the Gen-
tian CRP test at CRP ranges ≥50 mg/l and an only
slightly higher inter-assay CV of 4.1–4.7% (Table 6) still
lying below the data of the ELISA test. For a previously
developed automated immunoturbidimetric canine CRP
assay, intra- and inter-assay CVs <5% and ≤11%, respect-
ively [40] were reported which are comparable to the
CVs found in the current and previous studies. The
drawback of the previous canine CRP assay, however,
was that it was never commercially available. For CRP
concentrations >26.5 mg/l, the CVs reported in the pre-
vious study evaluating the Gentian Canine CRP Im-
munoassay on the Abbott Architect c4000 were
comparable to our results obtained for the clinically rele-
vant concentration levels B-D) (Table 6). For lower CRP
concentrations, intra-assay CVs were not calculated in
the previous method validation study by Hillström et al.
However, an SD of 0.39 mg/l was obtained for a sample
with a CRP concentration of 6.8 mg/l which was consist-
ent with a CV of 5.7% and thus comparable to the inter-
assay CV observed here for a similar CRP concentration
level. The CV of 5.8% observed by Muñoz-Prieto et al.
for a low CRP concentration of ~10 mg/l was also com-
parable to our and the previous results. Excellent correl-
ation for the Gentian CRP test with the compared assay
was shown in the current and both previous studies
(Table 6).
When regarding the rationale behind the method val-
idation study performed here, assessment of TEobs is an
essential point of each method comparison experiment
Fig. 5 Bland-Altman difference plot for canine C-reactive protein
(CRP) measured in canine serum samples and canine lithium heparin
(Li-Hep) samples with a Gentian Canine CRP Immunoassay. The black
line is consistent with the zero line. The blue line indicates the mean
bias and its 95%-confidence interval (green dotted line). The dotted
brown line is consistent with the ±1.96 standard deviation (SD) of
the mean absolute bias indicating the limits of agreement. The red
line indicates the desired maximum total allowable error (TEdes) of
29.6% [32] for measurement of canine CRP
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[29]. In our study, observed CVs and TEs were lower
than recommended desirable quality specification pub-
lished in the addendum of the allowable total error
guidelines of the ASVCP [32]. As the quality specifica-
tions published by the ASVCP are based on biological
variation, they have been considered too stringent for
method validation studies [32]. Nevertheless, they were
used in this study as no other quality specifications are
available for dogs. Even in human studies, quality speci-
fications for CRP are based on biological variation. Inter-
estingly, TEdes for CRP reported for people is 56.6% [41]
and thus markedly higher than the recommended desir-
able TEdes given for dogs of 29.58% and even slightly
higher than the recommended minimally acceptable TE
for dogs of 44.37% [32]. Moreover, national recommen-
dations are available for people such as the German Rili-
BÄK quality specifications (i.e., Guidelines (= RichtLinie
“Rili”) of the German Federal Medical Council (= Bun-
desärztekammer “BÄK”) [42], for which unofficial trans-
lations [43] have been performed to allow an
international use. Overall, German RiliBÄK quality spec-
ifications are most stringent as only deviations of 13.5%
are allowed. Interestingly, they are comparable with the
recommended TEopt for canine CRP of 14.79% published
in the ASVCP guidelines [32]. TEopt being comparable
with German RiliBÄK quality specifications has been
also observed previously for hematology measurands
[44]. For CRP concentrations >58 mg/dl, TEobs was even
below these most stringent quality specifications. For
lower CRP concentrations close to physiologic values,
TEobs was higher which was mainly based on a higher
CV. Despite all advantages of the calculation of TEobs
(encompassing various sources of error by the inclusion
of imprecision and bias) [45], it has to be considered
Table 6 Comparison of observed quality parameters for the Gentian Canine CRP Immunoassay run on three different analyzers
Quality parameters Gentian CRP ABX Pentra 400 Abbott Architect c4000a Olympus AU600b
Limit of quantification (mg/l) 4.0c 6,8d 5.4e
Linearity (mg/l) 4–281 6.8–1201 ~5–100
Recovery (%) 90–105 116–123 105–118
No prozone effect (mg/l) ≤ 676 ≤ 1200 ≤ 400
Precision
CRP range (mg/l): < 270; > 25 < 270; > 25 ≤ 100, ≥ 50
Intra-assay CV (%) 0.7–1.9 0.5–1.7 1.0–1.3
Inter-assay CV (%)
- Between run CV (%) 0.9–2.1 0.0–0.3 n.d.
- Between day CV (%) 1.1–4.6 1.1–1.9 4.1–4.7
No Interference up to
- Hemoglobin (g/l) 5 10 n.d.
- Bilirubin (mg/l) 800 n.d. n.d.
- Triglycerides (g/l) 10 10 n.d.
Method comparison
Reference method Randox Canine CRP assay Randox Canine CRP assay Olympus CRP
- rs 0.98 0.995 0.96
- intercept -1.18 7.3 n.d.
- slope 0.99 0.92 n.d.
- mean constant bias (%) 5.2 n.d. 41.0–70.5f
- TEobs (%) (~CRP 7–60 mg/l) 9.5–20.9 n.d. 50.4–82.6
f
(~CRP > 100 mg/l) 7.0–8.9 n.d. n.d
Sample type comparison small impact n.d. n.d.
The assay was evaluated independently on the ABX Pentra 400 and compared to the data of the previous validation on the Abbott Architect c4000 and on the
Olympus AU600.
Abbreviations: n.d. not done, CV coefficient of variation, TEobs observed total allowable error
a(Hillström et al. 2014) b(Muñoz-Prieto et al.2017)cbased on the desirable CV < 12.16%, dbased on desirable TE < 29.58%; both published in the addendum of the
Total allowable error (TE) guidelines of the American College of Veterinary Clinical Pathology [32], ebased on CV < 20% (Escribano et al. 2012). f calculated based
on the data of healthy and diseased dogs evaluated by Muñoz-Prieto et al.: healthy dogs: bias% ¼ median control−median testmean of the medians ¼
2:82mgl −1:35
mg
l
2:82−1:35ð Þ:2 x100%≈70:5%;
TEobs = bias % + 2CV% = 70.5% + 2 × 6.05% = 82.6%
dogs with inflammatory conditions: bias% ¼ 73:7
mg
l −48:6
mg
l
73:7þ48:6ð Þ:2 x100%≈41:0%;TEobs = 41.0% + 2 × 4.70% = 50.4%
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that also the TEobs is not a perfectly objective quality
parameter as it is dependent on the reference method
used to calculate the bias as was shown before for
hematology analyzers [44]. At the moment, there is no
consensus about the methodology for bias determination
for quality assessments. A high bias does not necessarily
indicate a poor assay performance but might be solely
induced by differences in the test protocol [46]. Only if
the reference method can be considered as a current
gold standard, a high bias has to be interpreted as a defi-
cient quality performance. If the quality data of the
current study are compared to the bias and TEobs calcu-
lated based on data of the previous method comparison
with another human based CRP assay [28] at for clinical
decisions relevant CRP levels, major differences can be
detected which may mainly be due to the different refer-
ence method applied (Table 6). Hillström et al. [26] used
the same reference assay as was used in our study but
did not provide data for an estimation of the TEobs. At
the moment there is no superior alternative to the as-
sessment of TEobs. Even the use of the TE as quality
standard is not without limitations as there are several
methods of its determination (i.e, derived on experts´
opinion, human quality specifications or biological vari-
ation [44]) which might come to different results. For
the canine CRP, only a TE derived from biological vari-
ation is available, however, it has to be considered that
the analytical method and the analyzer initially used for
its determination have an impact on the results. Analysis
of possible interferences of hemolysis, hyperbilirubine-
mia and lipemia on the assay performance revealed no
interferences in clinically relevant concentrations up to
5 g/l hemoglobin, 800 mg/l bilirubin and 10 g/l soy bean
oil (Intralipid). The absence of interference of lipemia
and hemolysis with the CRP measurement was also con-
firmed in the previous study evaluating the species-
specific Gentian Canine CRP Immunoassay [26] (Table
6), however, the potential interfering effect of bilirubin
was not assessed previously. To the author’s knowledge,
this is the first time effects of hyperbilirubinemia are in-
vestigated on the Gentian Canine CRP Immunoassay.
The lack of interference effects has to be claimed as a
major advantage in CRP analysis as associated metabolic
states frequently occur in patients with inflammatory
and infectious diseases [26]. In contrast, significant in-
terferences for all three substances were noted for a
commercial solid phase sandwich immunoassay (Tri-
delta Phase Range Canine C-reactive Protein Assay; Tri-
delta Development, Bray, Ireland) although the low
magnitude of the differences did not appear of relevance
for clinical interpretation of the test [47].
To the authors´ knowledge, the effect of the sample
type (heparinized plasma as an alternative to serum) has
not been evaluated before for the Gentian Canine CRP
Immunoassay. However, there are data available for the
dog-specific CRP ELISA (Tridelta Phase Range Canine
C-reactive Protein Assay, Tridelta Development, Bray,
Ireland). As in our study, there was no major difference
(P = 0.008) in CRP results measured in heparin plasma
or serum, although in contrast to our findings, the re-
sults tended to be slightly but insignificantly higher in
heparin plasma than in serum [47]. As CRP measure-
ments in heparin plasma showed a similar CV than
those performed in serum samples, it can be concluded
that both heparin plasma and serum can be used. Due to
the small bias, however, follow-up examinations should
be ideally performed in the same sample type.
Conclusion
The results of this study are comparable to the findings
observed during the previous evaluation of the canine
species-specific CRP test run on different analyzers [26,
28]. The good performance of the test enables its appli-
cation to several types of large bench top analyzers.
However the discrepant findings between the current
and previous studies such as the CRP concentration at
which a prozone effect occurs, linearity range and LoQ
should be specifically evaluated for each analyzer and la-
boratory performing the test.
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